Topotecan

General Toxicity Notes
Myelosuppressive and may aggravate uremic predisposition to hemorrhage and infection.
Excreted Unchanged %
40
Half-Life (Normalesrd) Hours
4-6/Prolonged
Plasma Protein Binding %
No data
Volume Of Distribution L/Kg
40
Dose For Normal Renal Function
5-20 mg/m2 q1-3wk
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
75% [B]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
50% [B]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
25% [B]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: Avoid, [D]
Supplement For Dialysis [Recommendation Level]: Pd
PD: Avoid, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: 0.75 mg/m2, assay available at St. Jude&#146; s, [B]
References
Herben VM, ten Bokkel Huinink WW, Beijnen JH. Clinical pharmacokinetics of topotecan. Clin Pharmacokinet. 1996; 31: 85-102. [PMID: 8853931] / O&#146; Reilly S, Rowinsky EK, Slichenmyer W, Donehower RC, Forastiere AA, Ettinger DS, et al. Phase I and pharmacologic study of topotecan in patients with impaired renal function. J Clin Oncol. 1996; 14: 3062-73. [PMID: 8955651]